Declaration of Audit Remuneration

RNS Number : 6267T

MaxCyte, Inc.

16 October 2017

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Declaration of Audit Remuneration

Maryland, USA - 16 October 2017: MaxCyte (LSE: MXCT, MXCR), in order to assist investors in considering the resolutions proposed ahead of its 2017 AGM, notes that the remuneration of the Company's auditors, Aronson LLC, for the financial year ended 2016 for audit-related services amounted to approximately $82,000 plus approximately $10,000 for non-audit related services.

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. GMT on 31 October 2017 at InterContinental London Park Lane, One Hamilton Place, Park Lane, London W1J 7QY, United Kingdom.

For further information, please contact:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	[phone]
Nominated Adviser and Broker Panmure Gordon
Freddy Crossley (Corporate Finance) Duncan Monteith Ryan McCarthy Tom Salvesen (Corporate Broking)	[phone]
Financial PR Adviser Consilium Strategic Communications
Mary-Jane Elliott Chris Welsh Lindsey Neville	[phone] [e-mail]

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges.   For more information, visit http://www.maxcyte.com/.

 

END

 

 

MSCDBBDGISBBGRU